Home › Research › Caregiving
Cost of disorders of the brain in Europe 2010
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M et al.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2011-09-15
Topic: Risk, prevention and care in population studies
Plain-language summary
Results The total cost of disorders of the brain was estimated at €798 billion in 2010. Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with patients' production losses. It should be noted that the revised estimate of those disorders included in the previous 2004 report constituted €477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004. Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe.
What this study adds
Evidence grade: High
This is a pooled review. This study estimated the total cost of brain disorders in Europe, including dementia. It provides economic information for planning but does not test any treatment or prevention for Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., et al. (2011). Cost of disorders of the brain in Europe 2010. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2011.08.008
Vancouver
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011. doi:10.1016/j.euroneuro.2011.08.008. PMID: 21924589.
BibTeX
@article{gustavsson2011-21924589,
author = {Gustavsson, A. and Svensson, M. and Jacobi, F. and Allgulander, C. and Alonso, J. and Beghi, E. and Dodel, R. and Ekman, M. and others},
title = {{Cost of disorders of the brain in Europe 2010}},
journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
year = {2011},
doi = {10.1016/j.euroneuro.2011.08.008},
pmid = {21924589},
url = {https://doi.org/10.1016/j.euroneuro.2011.08.008}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The total cost of disorders of the brain was estimated at €798 billion in 2010.
- Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with patients' production losses.
- It should be noted that the revised estimate of those disorders included in the previous 2004 report constituted €477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004.
- Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe.
Why it matters
This study estimated the total cost of brain disorders in Europe, including dementia. It provides economic information for planning but does not test any treatment or prevention for Alzheimer's.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 72/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology) |
| Journal's citation record | 2 / 4 | European Neuropsychopharmacology: journal h-index 158 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 7 / 7 | Cited 1,724 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 101.4 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 6 / 6 | Cited 140.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 3 / 4 | Cited 172 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Jes Olesen: h-index 138 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 38 institution(s) in 14 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21924589) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.euroneuro.2011.08.008
- PubMed: 21924589
- Original source →
- Free full text: Qucosa (Saxon State and University Library Dresden) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Caregiving from nearby years
Also in Caregiving
69 studies in the library are filed under Caregiving with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Caregiving hub.